Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: A 7-year assessment of a randomized controlled trial

Lung Cancer

Volumn 26, Issue 1, 1999, Pages 7-14

  Rosell, Rafael ^a   Gómez Codina, José ^b   Camps, Carlos ^c   Javier Sánchez, José ^d   Maestre, José ^e   Padilla, José ^b   Cantó, Antonio ^c   Abad, Albert ^a   Roig, Jordi ^f  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^d University Hospital of Madrid   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f Department of Pneumology   (Spain)

Author keywords

K ras gene mutations; Preresectional chemotherapy; Randomized trial; Resectable non small cell lung cancer

Indexed keywords

CISPLATIN; IFOSFAMIDE; MITOMYCIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDIASTINUM LYMPH NODE; MULTICENTER STUDY; ONCOGENE K RAS; POINT MUTATION; PRIORITY JOURNAL; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; EVALUATION STUDIES; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MIDDLE AGED; MITOMYCIN; PREOPERATIVE CARE;

EID: 0033215250     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(99)00045-8     Document Type: Article

References (35)

1. Martini N., Kris M.G., Flehinger B.J., Gralla R.J., Bains M.S., Burt M.E., Heelan R., McCormack P.M., Pisters K.M.W., Rigas J.R., Rusch V.W., Ginsberg R.J. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann. Thorac. Surg. 55:1993;1365-1374.
2. Hazuka M.B., Bunn P.A. Jr. Controversies in the nonsurgical treatment of stage III non-small cell lung cancer. Am. Rev. Respir. Dis. 145:1992;967-977.
3. Pass H.I., Pogrebniak H.W., Steinberg S.M., Mulshine J., Minna J. Randomized trial of neoadjuvant therapy for lung cancer:interim analysis. Ann. Thorac. Surg. 53:1992;992-998.
4. Rosell R., Gómez-Codina J., Camps C., Maestre J., Padille J., Cantó A., Mate J.L., Li S., Roig J., Olazabal A., Canela M., Ariza A., Skacel Z., Morera-Prat J., Abad A. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. New Engl. J. Med. 330:1994;153-158.
5. Roth J.A., Fossela F., Komaki R., Ryan M.B., Putnam J.B., Lee J.S., Dhingra H., De Caro L., Chasen M., McGavran M., Atkinson E.N., Ki Hong W. A randomized trial comparing preoperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J. Natl. Cancer Inst. 86:1994;673-680.
6. Roth J.A., Atkinson E.N., Fossella F., Komaki R., Ryan M.B., Putnam J.B., Lee J.S., Dhingra H., De Caro L., Chasen M., Ki Hong W. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer. 21:1998;1-6.
7. Elias A.D., Skarin A.T., Leong T., Mentzer S., Strauss G., Lynch T., Shulman L., Jacobs C., Abner A., Baldini E.H., Frei I.I.I. E., Sugarbaker D.J. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer. 17:1997;147-161.
8. a (abstr 1607).
9. Esteller M., Sanchez-Cespedes M., Rosell R., Sidransky D., Baylin B., Herman J.G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59:1999;67-70.
10. Rosell R., Moreno I., Maestre J., Olazabal A., Carles J., Barnadas A., Abad-Esteve A., Ribelles N., Canela M. Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced nonsmall-cell lung cancer: a meta-analytic review. J. Surg. Oncol. 45:1990;124-130.
11. Rosell R., López-Cabrerizo M.P., Astudillo J. Preoperative chemotherapy for stage IIIA non-small cell lung cancer. Curr. Opin. Oncol. 9:1997;149-155.
12. Rosell R. The integration of newer agents into neoadjuvant therapy. Semin. Oncol. 25(Suppl. 8):1998;24-27.
13. Sánchez-Cespedes M., Monzó M., Rosell R., Pifarré A., Calvo R., López-Cabrerizo M.P., Astudillo J. Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients. Ann. Oncol. 9:1998;113-116.
14. Shepherd F.A., Johnston M.R., Payne D., Burkes R., Deslauriers J., Cormier Y., de Bedoya L.D., Ottaway J., James K., Zee B. Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: a National Cancer Institute of Canada Clinical Trials Groups Study. Br. J. Cancer. 78:1998;683-685.
15. Skarin A., Jochelson M., Sheldon T., Malcom A., Olynyk P., Overholt R., Hunt M., Frei I.I.I. E. Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. J. Surg. Oncol. 40:1989;266-274.
16. Folkman J. Clinical applications of research on angiogenesis. New Engl. J. Med. 333:1995;1752-1763.
17. Rosell R. Chemotherapy plus surgery versus surgery alone in non-small-cell lung cancer. New Engl. J. Med. 330:1994;1757.
18. Jacobson D.R., Mills N.E. A highly sensitive assay for mutant ras genes and its application to the study of presentation and relapse genotypes in acute leukemia. Oncogene. 9:1994;553-563.
19. Rosell R., Molina F., Moreno I., Martinez E., Pifarré A., Font A., Li S., Skacel Z., Gómez-Codina J., Camps C., Monzó M., de Anta J.M. Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer. Lung Cancer. 12(Suppl.):1995;S59-S70.
20. Yamada T., Nakamori S., Ohzato H., Oshima S., Aoki T., Higaki N., Sugimoto K., Akagi K., Fujiwara Y., Nishisho I., Sakon M., Gotoh M., Monden M. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin. Cancer Res. 4:1998;1527-1532.
21. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50:1966;163-170.
23. Einhorn L.H. Neoadjuvant and adjuvant trials in non-small cell lung cancer. Ann. Thorac. Surg. 65:1998;208-211.
24. Vansteenkiste J., De Leyn P., Deneffe G., Menten J., Lerut T., Demedts M. Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a review. Eur. J. Cardiothoracic Surg. 13:1998;1-12.
25. Albain K.S., Rusch V.W., Crowley J.J., Rice T.W., Turrisi A.T. III, Weick J.K., Lonchyna V.A., Presant C.A., McKenna R.J., Gandara D.R., Fosmire H., Taylor S.A., Stelzer K.J., Beasley K.R., Livingston R.B. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group Phase II study 8805. J. Clin. Oncol. 13:1995;1880-1892.
26. Burkes R.L., Ginsberg R.J., Shepherd F.A., Blackstein M.E., Goldberg M.E., Waters P.F., Patterson G.A., Todd T., Pearson F.G., Cooper J.D., Jones D., Lockwood G. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto phase II trial. J. Clin. Oncol. 10:1992;580-586.
27. Eberhardt W., Wilke H., Stamatis G., Stuschke M., Harstrick A., Menker H., Krause B., Müeller M.R., Stahl M., Flasshove M., Budach V., Greschuchna D., Konietzko N., Sack H., Seeber S. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J. Clin. Oncol. 16:1998;622-634.
28. Faber L.P., Kittle C.F., Warren W.H., Bonomi P.D., Taylor I.V. S.G., Reddy S., Lee M.-S. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann. Thorac. Surg. 47:1989;669-677.
29. Mathisen D.J., Wain J.C., Wright C., Choi N., Carey R., Hilgenberg A., Grossbard M., Lynch T., Grillo H. Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer. J. Thorac. Cardiovasc. Surg. 111:1996;123-133.
30. Sridhar K.S., Thurer R., Kim Y., Fountzilas G., Davila E., Donnelly E., Charyulu K.K.N., Saldana M.J., Thompson T., Benedetto P., Raskin N., Beattie E.J. Multimodality treatment of non-small cell lung cancer: response to cisplatin, VP-16, and 5-FU chemotherapy and to surgery and radiation therapy. J. Surg. Oncol. 38:1988;193-215.
31. Strauss G.M., Herndon J.E., Sherman D.D., Mathisen D.J., Carey R.W., Choi N.C., Rege V.B., Modeas C., Green M.R. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J. Clin. Oncol. 10:1992;1237-1244.
32. Sugarbaker D.J., Herndon J., Kohman L.J., Krasna M.J., Green M.R. Results of Cancer and Leukemia Group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. J. Thorac. Cardiovasc. Surg. 109:1995;473-485.
33. Weiden P.L., Piantadosi S. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: a phase II study of the Lung Cancer Study Group. J. Natl. Cancer Inst. 83:1991;266-272.
34. 2) in stage IIIA (N2) non-small cell lung cancer (NSCLC). Lung Cancer 1997;18(Suppl 1):S64 (abstr 243).
35. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet. 352:1998;257-263.